Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results

Rhea-AI Summary

Monte Rosa Therapeutics (Nasdaq: GLUE) will present updated interim results from the Phase 1/2 study of the GSPT1-directed molecular glue degrader MRT-2359 in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients.

The company will host a live conference call and webcast on December 16, 2025 at 8:00 a.m. ET. The presentation will be available via Monte Rosa’s investor site under “Events & Presentations,” and an archived webcast will be accessible for 30 days after the event.

News Market Reaction

+0.86% 2.7x vol

14 alerts

+0.86% News Effect

+11.0% Peak in 29 hr 1 min

+$11M Valuation Impact

$1.23B Market Cap

2.7x Rel. Volume

On the day this news was published, GLUE gained 0.86%, reflecting a mild positive market reaction. Argus tracked a peak move of +11.0% during that session. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $11M to the company's valuation, bringing the market cap to $1.23B at that time. Trading volume was elevated at 2.7x the daily average, suggesting notable buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference time: 8:00 a.m. ET Conference date: December 16, 2025 Study phase: Phase 1/2 +1 more

4 metrics

Conference time 8:00 a.m. ET Scheduled webcast on December 16, 2025

Conference date December 16, 2025 MRT-2359 Phase 1/2 interim results presentation

Study phase Phase 1/2 Ongoing MRT-2359 study in mCRPC

Webcast archive duration 30 days Archived webcast availability after presentation

Market Reality Check

Price: $19.57 Vol: Volume 558,906 is about 0...

low vol

$19.57 Last Close

Volume Volume 558,906 is about 0.67x the 20-day average of 829,569, showing subdued trading ahead of the event. low

Technical Shares at $16.31 are trading above the 200-day MA $7.06, about 10.14% below the $18.15 52-week high and well above the $3.5001 52-week low.

Peers on Argus

GLUE was down 1.51% pre-announcement while key biotech peers were mixed: ENGN -5...

GLUE was down 1.51% pre-announcement while key biotech peers were mixed: ENGN -5.05%, CTNM -5.68%, FDMT -0.91%, with DRTS +1.2% and DSGN +1.4%. Moves do not indicate a unified sector trend.

Historical Context

5 past events · Latest: Nov 06 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 06	Earnings & updates	Positive	+5.7%	Q3 2025 results plus Novartis collaboration and clinical pipeline progress.
Nov 03	Investor conferences	Neutral	-6.1%	Planned CEO participation in multiple healthcare investor conferences.
Oct 24	Preclinical data	Positive	+7.3%	Preclinical MRT-6160 data showing broad immune activity and disease reduction.
Sep 15	Strategic partnership	Positive	+44.1%	Major Novartis collaboration with large upfront and milestone potential.
Sep 02	Investor conferences	Neutral	+2.5%	Announcements of attendance at Morgan Stanley and Stifel healthcare events.

Pattern Detected

Recent news events have consistently coincided with positive or constructive price reactions, including clinical and partnership updates, suggesting the stock has historically responded favorably to pipeline and business development news.

Recent Company History

Over the last six months, Monte Rosa reported multiple catalysts. A Sept 15, 2025 Novartis collaboration with a $120M upfront and up to $5.7B potential value drove a 44.07% move. Preclinical MRT-6160 data on Oct 24, 2025 saw a 7.32% gain. Q3 2025 results and business updates on Nov 6, 2025 coincided with a 5.69% rise. Conference participation headlines showed more muted, mixed moves. Today’s MRT-2359 interim update fits the pattern of frequent R&D news flow building on this pipeline narrative.

Market Pulse Summary

This announcement schedules an interim update from the ongoing Phase 1/2 study of MRT-2359 in heavil...

Analysis

This announcement schedules an interim update from the ongoing Phase 1/2 study of MRT-2359 in heavily pretreated mCRPC patients, with details to be discussed on December 16, 2025. It fits a pattern of frequent R&D communication, including prior preclinical and early clinical milestones. Investors may focus on efficacy and safety signals relative to earlier degrader programs, the durability of responses in metastatic disease, and how these results position MRT-2359 within Monte Rosa’s broader oncology strategy.

Key Terms

molecular glue degrader, GSPT1-directed, metastatic castration-resistant prostate cancer, mCRPC

4 terms

molecular glue degrader medical

"a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines"

A molecular glue degrader is a small drug-like molecule that acts like a tiny adhesive, sticking a specific disease-related protein to the cell’s natural disposal machinery so the protein is destroyed rather than merely blocked. Investors watch these compounds because they can turn previously untreatable targets into removable liabilities, potentially creating breakthrough therapies, shifting development risk, and offering strong commercial upside if clinical results and regulatory approval follow.

GSPT1-directed medical

"Phase 1/2 study of the GSPT1-directed MGD MRT-2359"

GSPT1-directed describes a therapy designed to target the GSPT1 protein, a molecule involved in the final step of making other proteins inside cells. By disabling or destroying GSPT1, these treatments aim to stop growth or trigger death in certain cancer cells; think of it as cutting the power to a factory’s packaging line so defective products can’t leave. For investors, this indicates a specific mechanism that can drive efficacy, safety profiles, biomarker strategies, and regulatory interest.

metastatic castration-resistant prostate cancer medical

"in heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC) patients"

An advanced form of prostate cancer that has spread beyond the prostate to other parts of the body (metastatic) and no longer responds to treatments that lower male hormones designed to starve the tumor (castration-resistant). It matters to investors because it defines a high unmet medical need with limited treatment options, so clinical trial results, new drug approvals, or safety setbacks can sharply change the valuation and prospects of companies working in this area; think of it as a weed that has spread and become resistant to the usual weedkiller.

mCRPC medical

"metastatic castration-resistant prostate cancer (mCRPC) patients"

mCRPC stands for metastatic castration‑resistant prostate cancer, a form of prostate cancer that has spread beyond the prostate and keeps progressing despite treatments that lower male hormones. It matters to investors because this stage is harder to treat, drives demand for new therapies, and often involves large, expensive clinical trials and regulatory decisions that can strongly influence a drug maker’s future revenue and stock value—think of it as a stubborn problem that creates both medical need and commercial opportunity.

AI-generated analysis. Not financial advice.

Conference call and webcast to be held at 8 a.m. ET on December 16, 2025

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Tuesday, December 16, 2025, at 8:00 a.m. ET. The webcast presentation will highlight interim clinical results from the ongoing Phase 1/2 study of the GSPT1-directed MGD MRT-2359 in heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC) patients.

A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com. Registration for the conference call is available at the following link. An archived version of the webcast will be made available for 30 days following the presentation.

About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology and neurology. For more information, visit www.monterosatx.com.

Investors
Andrew Funderburk
ir@monterosatx.com

Media
Cory Tromblee, Scient PR
media@monterosatx.com

FAQ

When will Monte Rosa Therapeutics (GLUE) present MRT-2359 Phase 1/2 interim results?

Management will present on December 16, 2025 at 8:00 a.m. ET.

What patient population is included in the MRT-2359 Phase 1/2 update for GLUE?

The update covers interim results in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) patients.

How can investors watch the Monte Rosa (GLUE) MRT-2359 presentation?

Watch live via the webcast on Monte Rosa’s investor site under Events & Presentations or join the conference call after registering.

Will the MRT-2359 webcast for GLUE be available after the live presentation?

Yes, an archived version will be available for 30 days following the presentation.

What drug is being discussed in Monte Rosa’s (GLUE) December 16, 2025 presentation?

The presentation highlights interim clinical results for the GSPT1-directed molecular glue degrader MRT-2359.

Is registration required to join Monte Rosa Therapeutics (GLUE) conference call for MRT-2359 results?

Yes, registration is available via the company’s provided conference call link.